Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Simcere Pharmaceutical Group

http://en.simcere.com/

Latest From Simcere Pharmaceutical Group

Local Generics Win Big In China's Latest National Tender

Only four multinationals, including Pfizer, had to make deep cuts to the prices of their off-patent drugs to outbid local generic competitors in China’s seventh round of centralized volume-based procurement. Among the foreign firms that lost out in the bidding, Eisai looks set to be dealt the heaviest blow in terms of market share.

China Pricing Strategies

Junshi’s COVID Antiviral Superior To Paxlovid? Some Caveats Unveiled

Unexpected protocol changes and a single-blind design for a Phase III head-to-head trial seem to have played to the advantage of Junshi’s oral derivative of Gilead’s antiviral remdesivir in COVID-19.

China Clinical Trials

Homegrown China Oral Antiviral Shows Early Promise

Junshi’s oral antiviral shows signs of effectiveness in treating patients with mild COVID-19 symptoms but more data are needed, caution researchers.

China Coronavirus COVID-19

China’s Home-Grown Oral COVID Antiviral Eyes Wider Population

Simcere is weighing options for SIM0417 in a Phase I trial in China as the first major domestically-developed potential rival to Pfizer’s oral COVID-19 antiviral Paxlovid. The study is likely to include wider patient groups ranging from those without symptoms to severe patients.

China Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Jilin Boda Pharmaceutical Co., Ltd.
    • ChinaVax
    • Master Luck Corporation Limited
    • Jiangsu Simcere Pharmaceutical R&D Co., Ltd.
    • Jiangsu Yanshen Biological Technology Stock Co., Ltd.
    • Nanjing Tung Chit Pharmaceutical Co., Ltd.
    • Shandong Simcere Medgenn Bio-Pharmaceutical Co. Ltd.
    • Wuhu Zhong Ren Pharmaceutical Co. Ltd.
    • Xiangao Investment Company Ltd.
    • Yantai Medgenn Co. Ltd.
    • Jiangsu Simcere Pharmaceutical Co., Ltd.
UsernamePublicRestriction

Register